Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group.Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for…
Minoryx Therapeutics and Neuraxpharm Group’s Development of a New CNS Therapy in Europe
